Kardigan, Inc.(KARD)

Biotechnology · Princeton, NJ

$13.49-1.75 (-11.48%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

PE Ratio: N/A

Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/E ratio is N/A as of 2026-10-06T21:37:21.961Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:37:21.961Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote price: 13.49
Unrounded diluted TTM EPS · period ending 2026-06-30: N/A

FMP input reference: 6dd2a4984e4340952b62e9ecd156f35eed99e3c78779d37ae6f95d3f5c845125

Forward PE Ratio|PEG Ratio|P/B Ratio|EPS|All Metrics

KARD PE Ratio Metrics

PE RATIO

N/A

KARD Competitors' PE Ratio

KARD

Kardigan, Inc.

Current

Market Cap

$1.21B

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DMRA

Damora Therapeutics, Inc.

vs KARD

Market Cap

$1.20B

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TYRA

Tyra Biosciences, Inc.

vs KARD

Market Cap

$1.21B

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INNV

Innovage Holding Corp.

vs KARD

Market Cap

$1.22B

PE Ratio

N/A

TTM Avg

92.39

3Y Avg

92.39

5Y Avg

92.39

MNKD

MannKind Corporation

vs KARD

Market Cap

$1.18B

PE Ratio

N/A

TTM Avg

65.92

3Y Avg

100.90

5Y Avg

100.90

CRON

Cronos Group Inc.

vs KARD

Market Cap

$1.23B

PE Ratio

18.14

TTM Avg

29.62

3Y Avg

28.16

5Y Avg

28.16

OMDA

Omada Health

vs KARD

Market Cap

$1.23B

PE Ratio

329.05

TTM Avg

351.15

3Y Avg

351.15

5Y Avg

351.15

ORIC

ORIC Pharmaceuticals, Inc.

vs KARD

Market Cap

$1.24B

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NKTR

Nektar Therapeutics

vs KARD

Market Cap

$1.14B

PE Ratio

N/A

TTM Avg

10.01

3Y Avg

10.01

5Y Avg

83.50

AMPH

Amphastar Pharmaceuticals, Inc.

vs KARD

Market Cap

$1.14B

PE Ratio

15.33

TTM Avg

11.54

3Y Avg

13.50

5Y Avg

19.40

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
Kardigan, Inc. (KARD)	$1.21B	N/A	N/A	N/A	N/A
Damora Therapeutics, Inc. (DMRA)vs ›	$1.20B	N/A	N/A	N/A	N/A
Tyra Biosciences, Inc. (TYRA)vs ›	$1.21B	N/A	N/A	N/A	N/A
Innovage Holding Corp. (INNV)vs ›	$1.22B	N/A	92.39	92.39	92.39
MannKind Corporation (MNKD)vs ›	$1.18B	N/A	65.92	100.90	100.90
Cronos Group Inc. (CRON)vs ›	$1.23B	18.14	29.62	28.16	28.16
Omada Health (OMDA)vs ›	$1.23B	329.05	351.15	351.15	351.15
ORIC Pharmaceuticals, Inc. (ORIC)vs ›	$1.24B	N/A	N/A	N/A	N/A
Nektar Therapeutics (NKTR)vs ›	$1.14B	N/A	10.01	10.01	83.50
Amphastar Pharmaceuticals, Inc. (AMPH)vs ›	$1.14B	15.33	11.54	13.50	19.40

P/E Comparison

Trailing P/E

N/A

Forward P/E

N/A

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$13.49

Forward EPS (Est.)

$-5.14

Forward P/E

N/A

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

See the Lowest P/E Ratio Stocks ranking →

PE Ratio: N/A

KARD PE Ratio Metrics

KARD Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics